Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dexamethasone

FDA-approved product (tablet, oral), marketed as Aeroseb-Dex, Decaderm, Decadron and 13 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Dexamethasone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Adrenal gland disease
  • Adrenal gland hyperfunction
  • Allergic conjunctivitis
  • Allergic rhinitis
  • Ankylosing spondylitis
  • Aplastic anemia
  • Asthma
  • Atopic eczema
  • Autoimmune thrombocytopenic purpura
  • Bursitis
  • Cancer
  • Chorioretinitis
  • Choroiditis
  • Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
  • Congenital adrenal hyperplasia
  • and 62 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids; Corticosteroids, moderately potent (group ii); Corticosteroids, moderately potent, other combinations; Corticosteroids, combinations for treatment of acne
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dexamethasone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dexamethasone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Interscalene Block With Liposomal Bupivacaine vs. Interscalene Block With Bupivacaine and Adjuvants

    NCT03845894 · start 2020-03-03

    Registered record
    Registry ID
    NCT03845894
    Conditions
    Shoulder Arthroplasty
    Interventions
    Liposomal bupivacaine; Bupivacaine with adjuvants
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2020-03-03
    Completion
    2022-06-25
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionShoulder Arthroplasty
    InterventionLiposomal bupivacaine; Bupivacaine with adjuvants
    PhasePhase 4
    Registry statusTerminated

  • "A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation"

    NCT04781335 · start 2020-02-20

    Registered record
    Registry ID
    NCT04781335
    Conditions
    Cataract
    Interventions
    Dexycu; Standard of Care post operative eye drops (steroid, antibiotic, NSAID)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-02-20
    Completion
    2022-12-22
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract
    InterventionDexycu; Standard of Care post operative eye drops (steroid, antibiotic, NSAID)
    PhasePhase 4
    Registry statusCompleted

  • Perioperative Dexamethasone on Postoperative Outcome in IBD

    NCT03456752 · start 2018-06-01

    Registered record
    Registry ID
    NCT03456752
    Conditions
    Inflammatory Bowel Diseases; Dexamethasone; Postoperative Ileus; Postoperative Complications
    Interventions
    Dexamethasone; Normal saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-06-01
    Completion
    2020-01-13
    Enrolment
    302

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammatory Bowel Diseases; Dexamethasone; Postoperative Ileus; Postoperative Complications
    InterventionDexamethasone; Normal saline
    PhasePhase 2
    Registry statusCompleted

  • A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

    NCT03234972 · start 2017-11-30

    Registered record
    Registry ID
    NCT03234972
    Conditions
    Multiple Myeloma
    Interventions
    Daratumumab; Velcade; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-11-30
    Completion
    2024-02-27
    Enrolment
    213

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionDaratumumab; Velcade; Dexamethasone
    PhasePhase 3
    Registry statusCompleted

  • Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction

    NCT02973880 · start 2017-10-15

    Registered record
    Registry ID
    NCT02973880
    Conditions
    Cataract Extraction; Cataract
    Interventions
    NETILDEX™ ophthalmic gel; NETILDEX™ eye drops solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-10-15
    Completion
    2018-12-30
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract Extraction; Cataract
    InterventionNETILDEX™ ophthalmic gel; NETILDEX™ eye drops solution
    PhasePhase 3
    Registry statusCompleted

  • Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

    NCT03104842 · start 2017-08-15

    Registered record
    Registry ID
    NCT03104842
    Conditions
    Multiple Myeloma
    Interventions
    Isatuximab; Carfilzomib; Lenalidomide; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2017-08-15
    Completion
    2026-09
    Enrolment
    246

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionIsatuximab; Carfilzomib; Lenalidomide; Dexamethasone
    PhasePhase 2
    Registry statusActive not recruiting

  • Reduced Dose of Prophylactic Dexamethasone for Elderly Patients Receiving Moderate Emetogenic Chemotherapy

    NCT03177317 · start 2017-05-01

    Registered record
    Registry ID
    NCT03177317
    Conditions
    Colonic Neoplasms
    Interventions
    Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-05-01
    Completion
    2020-01-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColonic Neoplasms
    InterventionDexamethasone
    PhaseNot applicable
    Registry statusCompleted

  • Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma

    NCT04063189 · start 2017-03-21

    Registered record
    Registry ID
    NCT04063189
    Conditions
    Multiple Myeloma in Relapse
    Interventions
    Clarithromycin Lenalidomide Dexamethasone (BiRd) Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2017-03-21
    Completion
    2020-02-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma in Relapse
    InterventionClarithromycin Lenalidomide Dexamethasone (BiRd) Regimen
    PhasePhase 2
    Registry statusUnknown

  • Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma

    NCT03023878 · start 2017-03-13

    Registered record
    Registry ID
    NCT03023878
    Conditions
    High-risk Diffuse Large B-Cell Lymphoma
    Interventions
    Blinatumomab; Investigator's Choice Chemotherapy; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-03-13
    Completion
    2019-10-28
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh-risk Diffuse Large B-Cell Lymphoma
    InterventionBlinatumomab; Investigator's Choice Chemotherapy; Dexamethasone
    PhasePhase 2
    Registry statusCompleted

  • Perineural Versus Systemic Dexamethasone to Prolong Regional Anesthesia in Front Foot Surgery

    NCT02904538 · start 2016-11-22

    Registered record
    Registry ID
    NCT02904538
    Conditions
    Pain Management After Surgery
    Interventions
    Dexamethasone; isotonic saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-11-22
    Completion
    2017-05-23
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain Management After Surgery
    InterventionDexamethasone; isotonic saline
    PhasePhase 3
    Registry statusCompleted

  • Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients

    NCT02970747 · start 2016-10-25

    Registered record
    Registry ID
    NCT02970747
    Conditions
    Multiple Myeloma in Relapse
    Interventions
    Carfilzomib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-10-25
    Completion
    2025-04-26
    Enrolment
    359

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma in Relapse
    InterventionCarfilzomib
    PhaseNot recorded
    Registry statusCompleted

  • Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

    NCT02916771 · start 2016-10

    Registered record
    Registry ID
    NCT02916771
    Conditions
    Smoldering Multiple Myeloma
    Interventions
    Ixazomib; Lenalidomide; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-10
    Completion
    2025-01-08
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmoldering Multiple Myeloma
    InterventionIxazomib; Lenalidomide; Dexamethasone
    PhasePhase 2
    Registry statusCompleted

  • The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM

    NCT02844309 · start 2016-05

    Registered record
    Registry ID
    NCT02844309
    Conditions
    Waldenström Macroglobulinemia
    Interventions
    Thalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-05
    Completion
    2020-05
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWaldenström Macroglobulinemia
    InterventionThalidomide
    PhasePhase 4
    Registry statusCompleted

  • PDD vs PAD to Treat Initially Diagnosed MM

    NCT02577783 · start 2015-10

    Registered record
    Registry ID
    NCT02577783
    Conditions
    Multiple Myeloma
    Interventions
    PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone; PAD regimen: bortizomib, dexamethasone and doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-10
    Completion
    2021-12
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionPDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone; PAD regimen: bortizomib, dexamethasone and doxorubicin
    PhasePhase 4
    Registry statusUnknown

  • Depot-opioids for Pre- and Postoperative Pain Relief After Primary Knee Arthroplasty.Tapentadol vs Oxycodone vs Placebo

    NCT02604446 · start 2015-09

    Registered record
    Registry ID
    NCT02604446
    Conditions
    Joint Diseases
    Interventions
    Tapentadol; Oxycodone; Placebo; usual pain treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-09
    Completion
    2019-02
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionJoint Diseases
    InterventionTapentadol; Oxycodone; Placebo; usual pain treatment
    PhasePhase 3
    Registry statusCompleted